Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
LifeVantage Corporation
Peer Reviewed Study from Louisiana State University, “Protandim®, a Fundamentally New Antioxidant Approach in Chemoprevention Using Mouse Two-Stage Skin Carcinogenesis as a Model,” Published in PLoS ONE Journal
May 12th, 2009
LifeVantage Corporation (OTCBB:LFVN) announced the findings from a Louisiana State University peer-reviewed study were published this week in the journal PLoS ONE, an international, peer-reviewed, open-access journal published by the Public Library of Science. The abstract from the study, conducted by Dr. Yunfeng Zhao and his colleagues at the Louisiana State University Health Sciences Center in Shreveport, LA, is presented below. The entire study can be found at: www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0005284. Abstract: Protandim, a Fundamentally New Antioxidant Approach in Chemoprevention Using Mouse Two-Stage Skin Carcinogenesis as a ModelJianfeng Liu, Xin Gu,...
Source: Cancer Weekly (2009-05-12)
|
